Can we use circulating tumor cells to identify high-risk patients?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Luca Bertamini, University of Turin, Turin, IT. We asked, Can we use circulating tumor cells to identify high-risk patients?

Bertamini reports the data from a study aiming to identify the best cut-off for circulating plasma cells to predict progression-free survival and overall survival. Together with well-known baseline prognostic features, analyzing circulating plasma cells by flow cytometry could add some information to the risk evaluation.